Zealand Pharma A/S · OMXCOP:ZEAL
Zealand Pharma A/S — Investor Day (November 2015)
40 slides from Zealand Pharma A/S's investor day presentation, Nov 18, 2015
Slide 1: Accelerating our business from peptides to patients
Accelerating our business from peptides to patients Britt Meelby Jensen President and CEO Capital Markets Day at Zealand 18 November 2015 Zealand Pharma A/S
Slide 2: Zealand's Capital Markets Day - Agenda
Zealand’s Capital Markets Day − Agenda Zealand – Business status, pipeline advances and strategy Britt Meelby Jensen, President and CEO at Zealand Q&A session Short Bowel Syndrome (SBS) – A growing disease area of high unmet needs Professor Palle Bekker Jeppesen, Medical Department of Gastroenterolo
Slide 3: Speaker presentations
Speaker presentations Britt Meelby Jensen Adam Steensberg Prof. Palle Bekker Dr. Kirsten Nørgaard President and CEO Senior Vice President, Jeppesen Specialist in Chief Medical Officer Head of Research at Endocrinology, the Medical Medical Leader of Department of the DiaCon-group at Gastroenterology
Slide 4: Zealand - A maturing biotech business from peptide to patient
Zealand - A maturing biotech business from peptide to patient Unique scientific expertise: Peptide-based medicines 1st medicine available for patients: Lyxumia® for Type 2 diabetes Mature out-licensed portfolio: Five products with Sanofi, Helsinn and Boehringer Ingelheim Growing proprietary pipeline
Slide 5: Management
Management Executive management Board of Directors Britt Meelby Jensen Mats Blom Hanne Leth Hillman Martin Nicklasson Rosemary Crane Catherine President & CEO SVP & CFO SVP for IR & Chairman Vice Chairman Moukheibir Communications Adam Steensberg Keld Fosgerau Michael J. Owen Alain Munoz Peter Benso
Slide 6: Peptide-based medicines - A growing class with broad therapeutic relevance
Peptide-based medicines - A growing class with broad therapeutic relevance Therapeutic Global peptide therapeutics market: USD 18.9 billion in 2013 * relevance of peptides ~7,000 native peptides in the human body Key role in essential physiological functions High biologic specificity and selec
Slide 7: Zealand's peptide expertise
Zealand’s peptide expertise - Innovation and dynamic cross-functional integration Turning peptides into medicines Strong IP portfolio and track record in peptide medicine development ~7,200 synthesized In vitro and Bioanalysis and peptides in vivo pharmacokinetics Pharmacology Medicinal Peptides wit
Slide 8: Zealand's portfolio
Zealand’s portfolio - Outlicensed products and growing proprietary pipeline Product / indication Preclinical Phase I Phase II Phase III Reg Marketed Outlicensed products and partnered projects Lyxumia® (lixisenatide) - ex-US Type 2 diabetes Lixisenatide - US Type 2 diabetes Lixilan (lixisenatide/ins
Slide 9: Zealand's business has matured substantially
Zealand’s business has matured substantially Proprietary pipeline Management and board changes Partnered / Outlicensed portfolio Elsiglutide advance into Phase IIb ELIXA demonstrate CV safety of Lixi Corporate / Other business ZP4207 multiple-dose – Helmsley Grant Lixi: Positive Get-Goal Duo II resu
Slide 10: Zealand share price performance and turnover
Zealand share price performance and turnover - Since the IPO in November 2010 400 2000 Zealand Pharma monthly turnover 1800 350 Zealand Pharma Nasdaq Biotechnology 1600 300 Monthly turnover (DKKm) OMX Nordic Healthcare 1400 250 Euro Stoxx Pharmaceuticals & Biotechnology 1200 DKK 200 1000 800 150 600
Slide 11: From peptide to patient - A diligent growth strategy
From peptide to patient - A diligent growth strategy Advance proprietary medicines Focus on specialty disease areas Focus on taking select medicines all Strengthened focus on specialty the way to registration, leveraging disease areas with high relevance for expected revenues from out-licensed pepti
Slide 12: Zealand in 2015+ - Building on strong trajectory for future direction
Zealand in 2015+ - Building on strong trajectory for future direction 1998 2015+ Proprietary Research, pre-clinical Development up Retain control through full pipeline and Phase I clinical to clinical proof- clinical development of development development of-concept selected projects Cardio- Focus o
Slide 13: Financial profile and 2015 guidance
Financial profile and 2015 guidance - Milestones, royalties and a solid cash position Revenue Net operating expenses Cash and equivalents EURm Royalty income Milestone income EURm Admin expenses R&D EURm 35 35 80 28 28 60 21 21 40 14 14 7 7 20 0 0 0 2010 2011 2012 2013 2014 2010 2011 2012 2013 2014
Slide 14: Products and projects under license collaboration
Products and projects under license collaboration Lixisenatide (Lyxumia®) – Sanofi LixiLan – Sanofi Elsiglutide – Helsinn Healthcare Two preclinical projects – Boehringer Ingelheim Zealand Pharma A/S page 14
Slide 15: GLP-1, a peptide hormone with multiple functions
GLP-1, a peptide hormone with multiple functions - Turned into a class of unique diabetes medications GLP-1 targets Physiological effects Therapeutic effects Pancreas Insulin Blood Glucagon glucose Stomach Gastric After emptying meal GLP-1 is released Brain into the blood Body Appetite stream weight
Slide 16: Effective diabetes management - Rationale and position for GLP-1 therapy
Effective diabetes management - Rationale and position for GLP-1 therapy Treatment algorithm for people with Type 2 diabetes Source: International Diabetes Federation Zealand Pharma A/S page 16
Slide 17: Lyxumia - Part of a fast growing class of medicines
Lyxumia® (lixisenatide) for Type 2 diabetes - Part of a fast growing class of medicines The GLP-1 market diabetes is currently growing by 25% (CAGR) Market value: USD 2.5 billion in 2014 Estimated USD 7 billion in 2020 Geographical market distribution: US 73% Europe 22% Source: IMS data and analyst
Slide 18: Lyxumia - First Zealand invented medicine on the market
Lyxumia® (lixisenatide) for Type 2 diabetes - First Zealand invented medicine on the market Marketed globally – under FDA review in the US Available for patients in more than 40 countries Invented by Zealand Sanofi plans additional launches in coming quarters US: Lixisenatide NDA accepted for
Slide 19: Challenge in Type 2 diabetes therapy
Challenge in Type 2 diabetes therapy - Effectively control both fasting and prandial glucose 24-hour pattern of hyperglycemia in type 2 diabetes Breakfast Lunch Dinner Plasma glucose mg/dL Post prandial 200 hyperglycemia Basal/fasting hyperglycemia 100 Normal glucose exposure 0 Time of 0600 1200 180
Slide 20: Lyxumia - Reduces post-prandial glucose throughout the day
Lyxumia® (lixisenatide) - Reduces post-prandial glucose throughout the day Breakfast Lunch Dinner Lixisenatide 20 PPG 20 mcg once daily 15 change Placebo 10 from 5 baseline 0 AUC -5 (mmol/L/h) -10 p=0.0082 p=0.0004 -15 -20 -25 p<0.0001 Source: Lorenz et al. Regulatory Peptides (E pub online) 2013;18
Slide 21: ELIXA CV outcome trial results
ELIXA CV outcome trial results - Lixisenatide is the only GLP-1 with proven CV safety Primary Outcome: CV death, MI, stroke or unstable angina • Placebo-controlled, 6,068 T2D patients at high CV risk • Demonstrate CV safety (as defined by FDA guidance) Source: ADA presentation on ELIXA results, June
Slide 22: Lixisenatide for insulin intensification - Advantages vs basal bolus regimen
Lixisenatide for insulin intensification - Advantages vs basal bolus regimen Percentage of patients achieving composite endpoints 32.2 22.2 Lixisenatide on top of glargine (n=297) 29.4 Glulisine QD on top of glargine (n=298) 26.1 24.2 Glulisine TID on top of glargine (n=295) 16.7 17.6 10.8 9.2 A1c<7
Slide 23: LixiLan for Type 2 diabetes - Lixisenatide and insulin glargine combination
LixiLan for Type 2 diabetes - Lixisenatide and insulin glargine combination product Basal insulin + GLP-1 effect on fasting and post-prandial glucose (illustrative) Fixed-dose, single-injection Insulin treatment + combination of lixisenatide and alone insulin glargine (Lantus®) Insulin + GLP-1 treat
Slide 24: Positive LixiLan results in proof-of-concept study
Positive LixiLan results in proof-of-concept study - HbA1c lowering to 6.3% Data LixiLan results Baseline A1c (%) 8.06 End point A1c (%) 6.3 Change in A1c (Abs. %) -1.8 Change in FPG (mg/dL) -60 % Achieving A1c <7% 84% Nausea (%) 7.5% Vomiting (%) 2.5% Change in Body Weight (kg) -1.0% Source: a 24-w
Slide 25: LixiLan Phase III program - Superior HbA1c reduction reported
LixiLan Phase III program - Superior HbA1c reduction reported in pivotal trials US target Type 2 Results and LixiLan-O trial diabetes populations outlook Both trials met » ~5.5 million 1,070 patients with Type 2 Primary Endpoint are not well diabetes insufficiently controlled of significant controll
Slide 26: Terms of the Sanofi license collaboration
Lyxumia® (lixisenatide) and LixiLan - Terms of the Sanofi license collaboration License agreement covers lixisenatide and combinations Sanofi has global development and commercial rights to lixisenatide and any combination product including lixisenatide All financing is covered by Sanofi Financi
Slide 27: Elsiglutide - Addressing a major unmet need in cancer therapy
Elsiglutide - Addressing a major unmet need in cancer therapy Chemotherapy induced diarrhea (CID) CID is a life-threatening condition associated with o Dehydration o Hospitalization o Markedly reduced quality of life o Sub-optimal cancer treatment No effective treatments available today 5-FU bas
Slide 28: Elsiglutide - A novel GLP-2 analogue in Phase IIb development
Elsiglutide - A novel GLP-2 analogue in Phase IIb development Elsiglutide Novel GLP-2 analogue invented by Zealand Global rights licensed to Helsinn in Cancer Supportive Care Helsinn is world-leading in Cancer Supportive Care Phase IIa results: Demonstrated effect in reducing the severity of c
Slide 29: Boehringer Ingelheim collaborations - New preclinical leads selected
Boehringer Ingelheim collaborations - New preclinical leads selected in both projects Glucagon/GLP-1 dual agonists for Potential revenues to Zealand Type 2 diabetes/obesity Up to EUR 365 million in total Oct 2015: Once-weekly preclinical lead candidate selected BI has global rights Zealand ret
Slide 30: Zealand's pipeline of proprietary products
Zealand’s pipeline of proprietary products Danegaptide ZP1848 GLP-2 for SBS ZP4207 glucagon rescue pen ZP4207 glucagon multiple-dose use ZP2929 glucagon/GLP-1 dual agonist Zealand Pharma A/S page 30
Slide 31: Danegaptide - Addressing reperfusion injury in AMI patients
Danegaptide - Addressing reperfusion injury in AMI patients An acute myocardial Severe long-term Acute action saves lives infarction (AMI) complications » » ST-elevated myocardial Percutaneous Coronary Restoration of blood flow infarction (STEMI) remains Intervention (PCI) or saves life, but the a s
Slide 32: Danegaptide - Restoration of blood flow cause reperfusion injuries
Danegaptide - Restoration of blood flow cause reperfusion injuries Myocardial ischemia Acute Myocardial ischemia Reducing the infarct size is key » » Infarct size correlates with mortality Acute and morbidity outcomes for patients Myocardial Essential for Reperfusion ischemia patient injuries when s
Slide 33: Danegaptide - Improving PCI outcome by reducing reperfusion injury
Danegaptide - Improving PCI outcome by reducing reperfusion injury 70 Myocardial ischemia in absence of reperfusion » 60 50 PCI / Fibrinolysis Infarct Size (%) » 40 Myocardial ischemia 30 with reperfusion 20 » » Danegaptide 10 5 Myocardial ischemia with 0 reperfusion and cardioprotection Source: Yel
Slide 34: Danegaptide - A novel mechanism of action
Danegaptide - A novel mechanism of action Cx43 Gap junction plaques Danegaptide is a gap-junction modifier A mimetic of the endogenous peptide AAP Prevents uncoupling of Connexin 43 (Cx43) gap junctions Thereby conferring tissue protection under and after ischemic and metabolic stress Connexin
Slide 35: Danegaptide - Cardioprotective effects shown in AMI models
Danegaptide - Cardioprotective effects shown in AMI models Danegaptide reduces infarct size in porcine model of ischemic reperfusion injuries 60 Immediate full reperfusion (IFR) p<0.05 50 60 min ischemia 180 min Reperfusion p<0.05 % Infarct size 40 Ischemic post-conditioning 30 60 min ischemia 180 m
Slide 36: Danegaptide - Strong safety profile shown in broad Phase I program
Danegaptide - Strong safety profile shown in broad Phase I program US Phase IA trial • N=72 healthy volunteers Single Ascending Dose • Up to 24 hours intravenous and oral dosing Safety, Tolerability, and • Safe and well tolerated Pharmacokinetic Study • Favorable PK profile Japanese Phase IA trial •
Slide 37: Danegaptide - Results from Phase II PoC trial expected in Q1 2016
Danegaptide - Results from Phase II PoC trial expected in Q1 2016 Phase II Proof-of-Concept trial (~600 patients) 600 STEMI Pt’s < 12 hours (and ongoing STE) Placebo-controlled, proof-of- concept, dose-finding trial 200 + 200 Danegaptide 200 Placebo Primary Endpoint: TIMI flow 2-3 Reduction in r
Slide 38: ZP2929 - Glucagon/GLP-1 dual agonist to treat diabetes/obesity
ZP2929 – Glucagon/GLP-1 dual agonist to treat diabetes/obesity Invented by Zealand A once-daily dual acting glucagon/GLP-1 peptide receptor agonist Part of a new class of investigational medicines for the treatment for patients with Type 2 diabetes and/or obesity Preclinical results Strong glu
Slide 39: ZP2929 - Proof-of-principle established in relevant models
ZP2929 - Proof-of-principle established in relevant models Significant HbA1c reduction Significant and sustained weight loss Diabetes model (db/db mice) Obesity model (DIOmice) 1.5 n = 11 Relative to day 0 HbA1c (%) 1.0 * 0.5 * 0.0 7 14 21 28 35 42 -0.5 *p<0.05 Days of Treatment ZP2929 ZP2929 Market
Slide 40: Question & Answer session
Question & Answer session Zealand Pharma A/S page 40